Efficacy and safety of Actovegin in the treatment of intermittent claudication: results of an international, multicenter, placebo-controlled, randomized, phase IIIb clinical trial (APOLLO)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of Actovegin in the treatment of intermittent claudication: results of an international, multicenter, placebo-controlled, randomized, phase IIIb clinical trial (APOLLO)

Published:2022-10 Issue:5 Volume:41 Page:
ISSN:0392-9590
Container-title:International Angiology
language:
Short-container-title:Int Angiol

Author:

SUCHKOV Igor A.,MZHAVANADZE Nina D.,BOGACHEV Vadim Y.,BOKUCHAVA Mamuka,KUZNETSOV Maxim R.,LUKYANOV Yury V.,KELIMBETOV Rustambek,PANG Hang,ARASLANOV Sergey A.

Publisher

Edizioni Minerva Medica

Subject

Cardiology and Cardiovascular Medicine

Link

https://www.minervamedica.it/pdf.php?cod=R34Y2022N05A0405

Reference14 articles.

1. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis

2. Actovegin®: a biological drug for more than 5 decades

3. Non-invasive evaluation of vasomotor and metabolic functions of microvascular endothelium in human skin

4. Multimodal approach to treatment of neurological complications of chronic brain ischemia

5. Gehstreckenzuwachs durch intraarteriell verabreichtes hämodialysat;Müller-Bühl U;Therapiewoche,1991

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PRISMA Systematic Literature Review, including with Meta-Analysis vs. Chatbot/GPT (AI) regarding Current Scientific Data on the Main Effects of the Calf Blood Deproteinized Hemoderivative Medicine (Actovegin) in Ischemic Stroke;Biomedicines;2023-06-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP